Your SlideShare is downloading. ×
  • Like
Global vaccine market forecast to 2017
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Now you can save presentations on your phone or tablet

Available for both IPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Global vaccine market forecast to 2017

  • 530 views
Published

Global vaccine market

Global vaccine market

Published in Health & Medicine
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
530
On SlideShare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
17
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Global Vaccine Market Forecast to 2017 © RNCOS Page 1
  • 2. Global Vaccine Market Forecast to 2017 © RNCOS Page 2 Table of Contents 1. Analyst View 2. Research Methodology 3. Global Vaccine Market Outlook to 2017 4. Major Vaccines: Current and Future Market Analysis 4.1 Pneumococcal 4.2 Influenza 4.3 Cancer 4.4 Polio 4.5 Varicella 4.6 Rotavirus 4.7 Meningococcal 4.8 DTP 4.9 Hepatitis 4.10 Measles, Mumps, and Rubella (MMR) 4.11 Japanese Encephalitis 4.12 Tuberculosis 4.13 Malaria 4.14 Rabies 4.15 Typhoid 4.16 HIV 5. Key Geographical Markets 5.1 US 5.2 Europe 5.3 Japan 5.4 China 5.5 India 5.6 Brazil 6. Competitive Landscape 6.1 GSK 6.2 Sanofi-Pasteur 6.3 Pfizer 6.4 Merck 6.5 Novartis 6.6 Emergent Biosolutions 6.7 AstraZeneca Plc. 6.8 Baxter International Inc. 6.9 BioCSL (CSL Biotherapies) 6.10 Dendreon Corporation 6.11 Takeda Pharmaceutical Company Limited 6.12 Crucell
  • 3. Global Vaccine Market Forecast to 2017 © RNCOS Page 3 List of Figures: Figure 3-1: Global - Vaccine Market (Billion US$), 2012-2017 Figure 4-1: Global - Causes of Deaths in Children (<5 Years) among Low-income Countries (%), 2011 Figure 4-2: Global - Pneumococcal Vaccine Market (Billion US$), 2012-2017 Figure 4-3: Global - Influenza Vaccine Market (Billion US$), 2012-2017 Figure 4-4: Global - Cancer Vaccine Market (Billion US$), 2012-2017 Figure 4-5: Global - Polio Vaccine Market (Billion US$), 2012-2017 Figure 4-6: Global - Varicella Vaccine Market (Billion US$), 2012-2017 Figure 4-7: Global - Rotavirus Vaccine Market (Billion US$), 2012-2017 Figure 4-8: Global - Meningococcal Vaccine Market (Billion US$), 2012-2017 Figure 4-9: Global - Number of Diphtheria Incidences by Region (2009 & 2010) Figure 4-10: Global - Number of nTetanus Incidences by Region (2009 & 2010) Figure 4-11: Global - Number of tTetanus Incidences by Region (2009 & 2010) Figure 4-12: Global - Number of Pertussis Incidences by Region (2009 & 2010) Figure 4-13: Global - DTP Vaccine Market (Billion US$), 2012-2017 Figure 4-14: Global - Hepatitis Vaccine Market (Million US$), 2012-2017 Figure 4-15: Global - Number of Measles Incidences by Region (2009 & 2010) Figure 4-16: Global - Number of Mumps Incidences by Region (‘000), 2009 & 2010 Figure 4-17: Global - Number of Rubella Incidences by Region (2009 & 2010) Figure 4-18: Global - MMR Vaccine Market (Million US$), 2012-2017 Figure 4-19: Global - Japanese Encephalitis Market (Million US$), 2012-2017 Figure 4-20: Global - Sources for Funding in HIV Vaccine R&D (%), 2011 Figure 5-1: Global - Vaccine Market by Region (%), 2012 Figure 5-2: Global - Vaccine Market by Region (%), 2017 Figure 5-3: US - Vaccine Market (Billion US$), 2012-2017 List of Tables: Table 4-1: Pneumococcal Vaccine Market - Key Players and Vaccines Table 4-2: Key Pneumococcal Vaccines in Pipeline Table 4-3: Influenza Vaccine Market - Key Players and Vaccines Table 4-4: Key Influenza Vaccines in Pipeline Table 4-5: Global - Cancer Statistics in More Developed and Less Developed Regions (2008) Table 4-6: Cancer Vaccine Market - Key Players and Vaccines Table 4-7: Key Cancer Vaccines in Pipeline Table 4-8: Polio Vaccine Market - Key Players and Vaccines Table 4-9: Key Polio Vaccines in Pipeline To see full list of figures & tables visit: http://www.rncos.com/Report/IM491_fig.htm
  • 4. Global Vaccine Market Forecast to 2017 © RNCOS Page 4 Pneumococcal Pneumococcal disease causes a broad range of infections in people around the world. The bacterium responsible for the disease, pneumococcus causes pneumonia, meningitis, and sepsis (serious blood infection) and takes the lives of more than half a million children each year worldwide with Africa and Asia being the sensitive zone. Pneumonia is the most common form of serious pneumococcal disease and accounts for xx% of children’s deaths in developing countries. Around xx% of the cases affect children under the age of 5 Years and at risk are elderly and children under 2 Years. Figure 4-1: Global - Causes of Deaths in Children (<5 Years) among Low-income Countries (%), 2011 Pneumonia Diarrhoea Malaria Prematurity Birth Asphyxia Neonatal Sepsis Congenital Abnormalities HIV/AIDS Injuries Measles Others Source: Pfizer’s Prevnar 13/Prevenar 13 is the most selling vaccine in the market. The vaccine generated revenue of around US$ xx Billion in 2012. The vaccine is a 13-valent pneumococcal conjugate vaccine for the prevention of various syndromes of pneumococcal disease in infants and young children and in adults 50 years of age and older Prevnar 13/Prevenar 13 for use in infants and young children is marketed in the U.S. for the prevention of invasive pneumococcal disease caused by the 13 serotypes in Prevnar 13 and otitis media caused by the seven serotypes in Prevnar, and in the EU and many other international markets for the prevention of invasive pneumococcal disease, otitis media and pneumococcal pneumonia caused by the vaccine serotypes Prevenar 13 for use in adults 50 years of age and older has been approved in over 55 countries. On January 25, 2013, the US FDA granted approval for the expansion of Prevnar 13 for use in children ages 6 through 17 years for active immunization for the prevention of invasive disease caused by the 13 vaccine serotypes. EU approval for use in children 6 through 17 years of age was received on January 7, 2013. Other important products in the pneumococcal vaccine market include GSK’s Synflorix and Merck’s Pneumovax 23 which generated estimated revenue of around US$ xx Million each. Cont… SSaammppllee SSeeccttiioonnss ffrroomm tthhee RReeppoorrtt To purchase the full report visit: http://www.rncos.com/Report/IM491.htm
  • 5. Global Vaccine Market Forecast to 2017 © RNCOS Page 5 India India, with the world’s second-largest population and a high incidence rate of all major adult and pediatric diseases is a huge potential market for all leading vaccine manufacturers. Several multinational companies consider India as the key market for vaccines with the national immunization program (NIP) gaining more popularity. At present, exports have a major share (around xx%) in the Indian vaccine market. Figure 5-7: India - Share of Domestic Consumption and Exports in Vaccine Market (2012) Domestic Consumption Exports Source: RNCOS The vaccine market in India is at an early growth stage, but due to factors like rising immunization programmes by government and increased disease awareness, the sector is expected to perform well in the future. The Global Alliance for Vaccines and Immunisation (GAVI) has also proposed a US$ xx Million grant to the Indian Government for immunization of xx Million newborns with pentavalent vaccines which, if accepted, will lead to additional business from India. Moreover, the country offers good research climate and better services to global players in the vaccine market. Taking into consideration all the above-mentioned factors, major industry players are expected to enter the Indian market through collaborations or agreements to tap the sector. Growth in the Indian vaccine market is also anticipated to be driven by both the strong demand in the domestic market as well as an increase in exports owing to an increase in demand from the WHO, GAVI, and the developing countries. On the back of these factors, Indian vaccine market is expected to grow at a CAGR of around xx% between 2012 and 2017 to record around US$ xx Billion. At present, a large chunk of the market is owned by domestic firms including Serum Institute of India, Shantha Biotech, Indian Immunological, Panacea Biotech, Venketeshwara Hatcheries, and many more. Among the foreign players, GSK, Sanofi-Pasteur, Merck & Co., and others dominate the market. Cont… To purchase the full report visit: http://www.rncos.com/Report/IM491.htm
  • 6. Global Vaccine Market Forecast to 2017 © RNCOS Page 6 Research Methodology Our dedicated team of industry experts intensively monitored and analyzed the healthcare industry scenario of almost all major economies in the world. The team found that due to rising healthcare cost and increasing prevalence of various severe diseases, the consumer behavior has changed drastically. Now, consumers prefer vaccines as preventive measures rather than relying upon treatments. This has boosted the demand of vaccines in the world, resulting in a generation of greater profits for vaccine players. This led us to study the global vaccine industry and explore various growth opportunities in the market. The snapshot of our thorough research approach includes: Secondary Research The research process begins with exhaustive secondary research on internal and external sources being carried out to source qualitative and quantitative information relating to each market. The secondary research sources that are typically referred to include, but are not limited to: • Company websites, annual reports, financial reports, broker reports, investor presentations and SEC Filings • Industry trade journals, Internal and external proprietary databases (EIU, One-source, Nexis, Hoovers etc.) • National government documents, statistical databases and market reports • News articles, press releases and web-casts specific to the companies operating in the market Primary Research RNCOS conducts numerous primary interviews every year with industry participants and commentators in order to validate its data and analysis. A typical research interview fulfills the following functions: • It provides first-hand information on the market size, market trends, growth trends, competitive landscape, future outlook, etc. • Helps in validating and strengthening the secondary research findings • Further develops the Analysis Team's expertise and market understanding Primary research involves e-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies. Estimations and Forecasts The forecast provided is based on the result of our economic and judgmental analysis and past drivers, challenges, and opportunities for expansion. While forecasting, we have given due consideration to the current industry trends. In this way, our report depicts the most unbiased picture of the global vaccine market.
  • 7. Global Vaccine Market Forecast to 2017 © RNCOS Page 7 ABOUT Established in 2002, RNCOS is a premier source of healthcare research and information provider. We bring first-hand information and prudent analysis on the healthcare industry, technologies, economic and non-economic market parameters, potential markets, and key competitors, to help clients identify prospective growth areas and gain competitive edge. All our research solutions are supported by robust, evidence-based analytics grounded by extensive primary and secondary research. They not only provide the most up-to-date market figures, forecasts, and pipeline data, but offers valuable insights on successes and failures in the ever-competitive healthcare industry. Our reports provide strategic information for investment bankers, companies, management consultants, trade associations, corporate executives and business analysts. Our work helps them to support critical business decisions such as, entering new markets, launching and enhancing products, making acquisitions or strategic investments, unseating competitors and more. WORK PROCESS Contact Information B 129, Sector 6, Noida, India Ph.: + 91 (120) 4224700 Extn. 203/208 Fax: + 91 (120) 4224707 Email: marketing@rncos.com Website: www.rncos.com
  • 8. Global Vaccine Market Forecast to 2017 © RNCOS Page 8 Disclaimer The findings, conclusions and recommendations that RNCOS delivers are based on information gathered in good faith from both primary and secondary sources. Neither the company nor any of its employees makes any warranty, express or implied, including the warranties of merchantability and fitness for a particular purpose, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of RNCOS. Such protected material, however, may be used under the terms of "fair use" as defined in the copyright laws, which generally permits use for non-commercial educational purposes such as teaching, research, criticism, and news reporting. Unless otherwise stated, the copyright, database rights, and other similar rights of this publication are solely owned by RNCOS. You are permitted to print or download extracts from this material for your personal use only. None of this material may be used for any commercial or public use. No part of research material appearing may be reproduced, stored in or transmitted on any other Website without written permission of RNCOS and any payments of a specified fee. Requests to republish any material may be sent to us and it is our sole discretion to allow it or not.